

DAFTAR PUSTAKA

- Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet (London, England)*, 399(10325), 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Anuj, S. N., *et al* (2009). Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction assay targeting the *ecfX* and the *gyrB* genes. *Diagnostic Microbiology and Infectious Disease*, 63(2), 127-131. <https://doi.org/10.1016/j.diagmicrobio.2008.09.018>
- Anuj, S. N, *et al* (2011). Rapid single-nucleotide polymorphism-based identification of clonal *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. *Clinical Microbiology and Infection*, 25(11), 1402.e1-1402.e7. <https://doi.org/10.1016/j.cmi.2019.06.020>
- Atmanto, Y. K. A. A., Asri, L. A., and Kadir, N. A. (2022). Media Pertumbuhan Kuman. *Jurnal Medika Hutama*, 4(01 Oktober), 3069-3075.
- Berrazeg, M., *et al* (2015). Mutations in β -Lactamase AmpC Increase Resistance of *Pseudomonas aeruginosa* Isolates to Antipseudomonal Cephalosporins. *Antimicrobial agents and chemotherapy*, 59(10), 6248–6255. <https://doi.org/10.1128/AAC.00825-15>
- Bossuyt, P. M *et al* (2015). STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ (Clinical research ed.)*, 351, h5527. <https://doi.org/10.1136/bmj.h5527>
- Botelho, J., Grosso, F., and Peixe, L. (2019). Antibiotic resistance in *Pseudomonas aeruginosa* - Mechanisms, epidemiology and evolution. *Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy*, 44, 100640. <https://doi.org/10.1016/j.drup.2019.07.002>
- Bou, G., Fernández-Olmos, A., García, C., Sáez-Nieto, J. A., and Valdezate, S. (2011). Métodos de identificación bacteriana en el laboratorio de microbiología. *Enfermedades Infecciosas y Microbiología Clínica*, 29(8), 601-608. <https://doi.org/10.1016/j.eimc.2011.03.012>
- Boushra, M. R., Gad, G. F. M., Hassuna, N. A., Waly, N. G. F., and Ibrahim, R. A. (2024). Phenotypic and genotypic assessment of fluoroquinolones and aminoglycosides resistances in *Pseudomonas aeruginosa* collected from Minia hospitals, Egypt during COVID-19 pandemic. *BMC infectious diseases*, 24(1), 763. <https://doi.org/10.1186/s12879-024-09605-5>

- Burns, J. L., *et al* (2000). Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Journal of clinical microbiology*, 38(5), 1818–1822. <https://doi.org/10.1128/JCM.38.5.1818-1822.2000>
- Burns, J. L., *et al* (2003). Use of real-time PCR with multiple targets to identify *Pseudomonas aeruginosa* and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. *Journal of Clinical Microbiology*, 41(9), 4312–4317. <https://doi.org/10.1128/jcm.41.9.4312-4317.2003>
- Bustin, S. A., and Nolan, T. (2020). RT-qPCR Testing of SARS-CoV-2: A Primer. *International journal of molecular sciences*, 21(8), 3004. <https://doi.org/10.3390/ijms21083004>
- Bustin, S. A., *et al* (2013). The need for transparency and good practices in the qPCR literature. *Nature methods*, 10(11), 1063–1067. <https://doi.org/10.1038/nmeth.2697>
- Cabot, G., *et al* (2014). *Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. *Antimicrobial agents and chemotherapy*, 58(6), 3091–3099. <https://doi.org/10.1128/AAC.02462-13>
- Cassini, A., *et al* (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *The Lancet. Infectious diseases*, 19(1), 56–66. [https://doi.org/10.1016/S1473-3099\(18\)30605-4](https://doi.org/10.1016/S1473-3099(18)30605-4)
- Cheraghi, E. S., and Ghiasian, M. (2024). Molecular characterization of efflux pumps in beta-lactam resistant *Pseudomonas aeruginosa*. *Medical Laboratory Journal*, 18(1), 33–42. <https://mlj.goums.ac.ir/article-1-1866-en.html>
- Corman, V. M., *et al* (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*, 25(3), 2000045. <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
- Cui, X., Zhang, H., and Du, H. (2019). Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy. *Frontiers in microbiology*, 10, 1823. <https://doi.org/10.3389/fmicb.2019.01823>
- Dahlan, M. S. (2010). *Besar Sampel dan Cara Pengambilan Sampel* (3rd ed.). Salemba Medika.
- Dedeić Ljubović, A., *et al* (2024). Predominance of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* strains in tertiary hospital in Sarajevo, Bosnia and Herzegovina. *Biomolecules & biomedicine*, 24(5), 1178–1185. <https://doi.org/10.17305/bb.2024.10406>

- Deschaght, P., *et al* (2010). Comparison of culture and qPCR for the detection of *Pseudomonas aeruginosa* in not chronically infected cystic fibrosis patients. *BMC microbiology*, 10, 245. <https://doi.org/10.1186/1471-2180-10-245>
- Doi Y. (2019). Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 69(Suppl 7), S565–S575. <https://doi.org/10.1093/cid/ciz830>
- Drancourt, M., Michel-Lepage, A., Boyer, S., and Raoult, D. (2016). The Point-of-Care Laboratory in Clinical Microbiology. *Clinical microbiology reviews*, 29(3), 429–447. <https://doi.org/10.1128/CMR.00090-15>
- Drawz, S. M., and Bonomo, R. A. (2010). Three decades of beta-lactamase inhibitors. *Clinical microbiology reviews*, 23(1), 160–201. <https://doi.org/10.1128/CMR.00037-09>
- Dubourg, G., and Raoult, D. (2022). Emerging methodologies for pathogen identification in bloodstream infections. *Clinical Microbiology and Infection*, 28(2), 161-168. <https://doi.org/10.1016/j.cmi.2021.06.025>
- Egge, S. L., *et al*. (2025). 313. Genomic Features Associated with Non-susceptibility to Cefiderocol in *Pseudomonas aeruginosa* and Cross-resistance to Novel β -lactam/ β -lactamase Inhibitors in the Prospective Observational *Pseudomonas* (POP) study. *Open Forum Infectious Diseases*, 12(Suppl 1), ofae631.103. <https://doi.org/10.1093/ofid/ofae631.103>
- Ezraty, B., Gennaris, A., Barras, F., and Collet, J. F. (2017). Oxidative stress, protein damage and repair in bacteria. *Nature reviews. Microbiology*, 15(7), 385–396. <https://doi.org/10.1038/nrmicro.2017.26>
- Fang, T., Peng, L., Yang, T., Cai, Q., Li, H., and Cai, L. (2025). Development and evaluation of multiplex real-time PCR for rapid identifying major pathogenic mycobacteria from pulmonary and extrapulmonary clinical samples. *Heliyon*. [https://www.cell.com/heliyon/fulltext/S24058440\(24\)17415-4](https://www.cell.com/heliyon/fulltext/S24058440(24)17415-4)
- Feltman, H., *et al* (2001). Prevalence of type III secretion genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *Microbiology (Reading, England)*, 147(Pt 10), 2659–2669. <https://doi.org/10.1099/00221287-147-10-2659>
- Freschi, L., *et al* (2019). The *Pseudomonas aeruginosa* Pan-Genome Provides New Insights on Its Population Structure, Horizontal Gene Transfer, and Pathogenicity. *Genome biology and evolution*, 11(1), 109–120. <https://doi.org/10.1093/gbe/evy259>
- Green, M. R., and Sambrook, J. (2018). The Basic Polymerase Chain Reaction (PCR). *Cold Spring Harbor protocols*, 2018(5), 10.1101/pdb.prot095117. <https://doi.org/10.1101/pdb.prot095117>

- Harris, P. N. A., Tambyah, P. A., and Paterson, D. L. (2015). β -lactam and β -lactamase inhibitor combinations in the treatment of extended-spectrum β -lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? *The Lancet Infectious Diseases*, 15(4), 475–485. [https://doi.org/10.1016/S1473-3099\(14\)70950-8](https://doi.org/10.1016/S1473-3099(14)70950-8)
- Hawkey, P. M., *et al* (2018). Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. *The Journal of antimicrobial chemotherapy*, 73(suppl_3), iii2–iii78. <https://doi.org/10.1093/jac/dky027>
- Holmes, A. H., *et al* (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *Lancet (London, England)*, 387(10014), 176–187. [https://doi.org/10.1016/S0140-6736\(15\)00473-0](https://doi.org/10.1016/S0140-6736(15)00473-0)
- Horcajada, J. P., *et al* (2019). Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections. *Clinical Microbiology Reviews*, 32(4), e00031–19.
- Humphries, R. M., and Linscott, A. J. (2015). Practical guidance for clinical microbiology laboratories: diagnosis of bacterial gastroenteritis. *Clinical microbiology reviews*, 28(1), 3–31.
- Jacoby G. A. (2009). AmpC beta-lactamases. *Clinical microbiology reviews*, 22(1), 161–182. <https://doi.org/10.1128/CMR.00036-08>
- Jones, T. L., *et al*. (2024). Respiratory Pathogens at Exacerbation in Chronic Bronchitis With Airway Bacterial Colonisation: A Cohort Study. *The Clinical Respiratory Journal*. <https://onlinelibrary.wiley.com/doi/pdf/10.1111/crj.13811>
- Juan, C., Moyá, B., Pérez, J. L., and Oliver, A. (2006). Stepwise upregulation of the *Pseudomonas aeruginosa* chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. *Antimicrobial agents and chemotherapy*, 50(5), 1780–1787. <https://doi.org/10.1128/AAC.50.5.1780-1787.2006>
- Juan, C., Torrens, G., González-Nicolau, M., and Oliver, A. (2017). Diversity and regulation of intrinsic β -lactamases from non-fermenting and other Gram-negative opportunistic pathogens. *FEMS microbiology reviews*, 41(6), 781–815. <https://doi.org/10.1093/femsre/fux043>
- Kadri, S. S., *et al* (2018). Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 67(12), 1803–1814. <https://doi.org/10.1093/cid/ciy378>

- Klockgether, J., and Tümmler, B. (2017). Recent advances in understanding *Pseudomonas aeruginosa* as a pathogen. *F1000Research*, 6, 1261. <https://doi.org/10.12688/f1000research.10506.1>
- Klockgether, J., Cramer, N., Wiehlmann, L., Davenport, C. F., and Tümmler, B. (2011). *Pseudomonas aeruginosa* Genomic Structure and Diversity. *Frontiers in microbiology*, 2, 150. <https://doi.org/10.3389/fmicb.2011.00150>
- Kocer, K., Boutin, S., Moll, M., and Nurjadi, D. (2024). Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant *Pseudomonas aeruginosa*, Germany 2019-21. *JAC-antimicrobial resistance*, 6(6), dlae183. <https://doi.org/10.1093/jacamr/dlae183>
- Kos, V. N., *et al* (2015). The resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility. *Antimicrobial agents and chemotherapy*, 59(1), 427–436. <https://doi.org/10.1128/AAC.03954-14>
- Kralik, P., and Ricchi, M. (2017). A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything. *Frontiers in microbiology*, 8, 108. <https://doi.org/10.3389/fmicb.2017.00108>
- Leber, A. L. (Ed.). (2016). *Clinical Microbiology Procedures Handbook* (4th ed.). ASM Press.
- Lee, J., and Zhang, L. (2015). The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein and cell*, 6(1), 26–41. <https://doi.org/10.1007/s13238-014-0100-x>
- Le Gall, F., *et al* (2013). Proposal of a quantitative PCR-based protocol for an optimal *Pseudomonas aeruginosa* detection in patients with cystic fibrosis. *BMC microbiology*, 13, 143. <https://doi.org/10.1186/1471-2180-13-143>
- Lister, P. D., Wolter, D. J., and Hanson, N. D. (2009). Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clinical microbiology reviews*, 22(4), 582–610. <https://doi.org/10.1128/CMR.00040-09>
- Livermore D. M. (1995). beta-Lactamases in laboratory and clinical resistance. *Clinical microbiology reviews*, 8(4), 557–584. <https://doi.org/10.1128/CMR.8.4.557>
- Livermore D. M. (2002). Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa*: our worst nightmare?. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*, 34(5), 634–640. <https://doi.org/10.1086/338782>
- Malhotra, S., Hayes, D., Jr, and Wozniak, D. J. (2019). Cystic Fibrosis and *Pseudomonas aeruginosa*: the Host-Microbe Interface. *Clinical microbiology reviews*, 32(3), e00138-18. <https://doi.org/10.1128/CMR.00138-18>

- Mark, B. L., Vocadlo, D. J., and Oliver, A. (2011). Providing β -lactams a helping hand: targeting the AmpC β -lactamase induction pathway. *Future microbiology*, 6(12), 1415–1427. <https://doi.org/10.2217/fmb.11.128>
- Maruri-Aransolo, A., *et al.* (2024). In vitro activity of cefiderocol in *Pseudomonas aeruginosa* isolates from people with cystic fibrosis recovered during three multicentre studies in Spain. *The Journal of antimicrobial chemotherapy*, 79(6), 1432–1440. <https://doi.org/10.1093/jac/dkae126>
- Mauch, R. M., *et al.* (2018). Mechanisms of humoral immune response against *Pseudomonas aeruginosa* biofilm infection in cystic fibrosis. *Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society*, 17(2), 143–152. <https://doi.org/10.1016/j.jcf.2017.08.012>
- Moradali, M. F., Ghods, S., and Rehm, B. H. (2017). *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Frontiers in cellular and infection microbiology*, 7, 39. <https://doi.org/10.3389/fcimb.2017.00039>
- Morgan, J. A., Rhodes, G., and Pickup, R. W. (1993). Survival of nonculturable *Aeromonas salmonicida* in lake water. *Applied and environmental microbiology*, 59(3), 874–880. <https://doi.org/10.1128/aem.59.3.874-880.1993>
- Moya, B., *et al.* (2009). Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. *PLoS pathogens*, 5(3), e1000353. <https://doi.org/10.1371/journal.ppat.1000353>
- Murray, C. J., *et al.* (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, 399(10325), 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Muteeb, G., Kazi, R. N. A., Aatif, M., Azhar, A., Oirdi, M. E., and Farhan, M. (2025). Antimicrobial resistance: Linking molecular mechanisms to public health impact. *SLAS discovery: advancing life sciences R & D*, 33, 100232. <https://doi.org/10.1016/j.slasd.2025.100232>
- Naylor, N. R., *et al.* (2018). Estimating the burden of antimicrobial resistance: a systematic literature review. *Antimicrobial resistance and infection control*, 7, 58. <https://doi.org/10.1186/s13756-018-0336-y>
- Nhan, N. T., *et al.* (2025). Performance characteristics of an automated, high-throughput RT-PCR assay for the detection of *Candida auris* on 3-point and nasal swabs. *Microbiology spectrum*, e0211424. Advance online publication. <https://doi.org/10.1128/spectrum.02114-24>
- Oliver, A., Mulet, X., López-Causapé, C., and Juan, C. (2015). The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy*, 21-22, 41–59. <https://doi.org/10.1016/j.drug.2015.08.002>
- Opota, O., Croxatto, A., Prod'homme, G., and Greub, G. (2015). Blood culture-based diagnosis of bacteraemia: state of the art. *Clinical microbiology and infection: the official publication of the European Society of Clinical*

Microbiology and Infectious Diseases, 21(4), 313–322.
<https://doi.org/10.1016/j.cmi.2015.01.003>

- Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J., and Cheng, Z. (2019). Antibiotic resistance in *Pseudomonas aeruginosa*: Mechanisms and alternative therapeutic strategies. *Biotechnology Advances*, 37(1), 177–192.
- Philippon, A., Arlet, G., and Jacoby, G. A. (2002). Plasmid-determined AmpC-type beta-lactamases. *Antimicrobial agents and chemotherapy*, 46(1), 1–11. <https://doi.org/10.1128/AAC.46.1.1-11.2002>
- Poole K. (2011). *Pseudomonas aeruginosa*: resistance to the max. *Frontiers in microbiology*, 2, 65. <https://doi.org/10.3389/fmicb.2011.00065>
- Pragasam, A. K., Veeraraghavan, B., Nalini, E., Anandan, S., and Kaye, K. S. (2018). An update on antimicrobial resistance and the role of newer antimicrobial agents for *Pseudomonas aeruginosa*. *Indian journal of microbiology*, 36(3), 303–316. https://doi.org/10.4103/ijmm.IJMM_18_334
- Prestinaci, F., Pezzotti, P., and Pantosti, A. (2015). Antimicrobial resistance: a global multifaceted phenomenon. *Pathogens and global health*, 109(7), 309–318. <https://doi.org/10.1179/2047773215Y.00000000030>
- Purssell, A., and Poole, K. (2013). Functional characterization of the NfxB repressor of the mexCD-oprJ multidrug efflux operon of *Pseudomonas aeruginosa*. *Microbiology (Reading, England)*, 159(Pt 10), 2058–2073. <https://doi.org/10.1099/mic.0.069286-0>
- Quale, J., Bratu, S., Gupta, J., and Landman, D. (2006). Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates. *Antimicrobial agents and chemotherapy*, 50(5), 1633–1641. <https://doi.org/10.1128/AAC.50.5.1633-1641.2006>
- Rehman, A., Jeukens, J., Levesque, R. C., & Lamont, I. L. (2021). Gene-Gene Interactions Dictate Ciprofloxacin Resistance in *Pseudomonas aeruginosa* and Facilitate Prediction of Resistance Phenotype from Genome Sequence Data. *Antimicrobial agents and chemotherapy*, 65(7), e0269620. <https://doi.org/10.1128/AAC.02696-20>
- Ruppé, E., Cherkaoui, A., Lazarevic, V., Emonet, S., and Schrenzel, J. (2017). Establishing Genotype-to-Phenotype Relationships in Bacteria Causing Hospital-Acquired Pneumonia: A Prelude to the Application of Clinical Metagenomics. *Antibiotics (Basel, Switzerland)*, 6(4), 30. <https://doi.org/10.3390/antibiotics6040030>
- Schmidtke, A. J., and Hanson, N. D. (2006). Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance. *Antimicrobial agents and chemotherapy*, 50(6), 2030–2037. <https://doi.org/10.1128/AAC.01458-05>
- Shaaban, M. T., Abdel-Raouf, M., Zayed, M., and Emara, M. A. (2024). Microbiological and molecular studies on a multidrug-resistant

- Pseudomonas aeruginosa* from a liver transplant patient with urinary tract infection in Egypt. *BMC Microbiology*, 24(1), 31. <https://doi.org/10.1186/s12866-024-03318-0>
- Shafira, M. L., Ethica, S. N., and Ernanto, A. R. (2022). Deteksi *Pseudomonas aeruginosa* Isolat Pus Luka Berbasis Polymerase Chain Reaction Menggunakan Gen *algD*. In *Prosiding Seminar Nasional Unimus* (Vol. 5).
- Šimundić, A. M. (2009). *Measures of diagnostic accuracy: Basic definitions*. *EJIFCC*, 19(4), 203-211. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975285/>
- SINAR-PAMKI. (2024). *Analisis Lengkap Pola Patogen dan Antibiotogram Indonesia 2023*. Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia (PAMKI)
- Srikumar, R., Paul, C. J., & Poole, K. (2000). Influence of mutations in the *mexR* repressor gene on expression of the *MexA-MexB-oprM* multidrug efflux system of *Pseudomonas aeruginosa*. *Journal of bacteriology*, 182(5), 1410–1414. <https://doi.org/10.1128/JB.182.5.1410-1414.2000>
- Streck, Inc. (n.d.). *ARM-D® Kit AmpC - Antibiotic Resistance Kits*. Retrieved October 25, 2024, <https://www.streck.com/products/molecular/antibiotic-resistance-kits/arm-d-kit-ampc/>
- Svec, D., Tichopad, A., Novosadova, V., Pfaffl, M. W., and Kubista, M. (2015). How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments. *Biomolecular detection and quantification*, 3, 9–16. <https://doi.org/10.1016/j.bdq.2015.01.005>
- Sverak, H. E., *et al* (2024). Cryo-EM characterization of the anhydromuropeptide permease AmpG central to bacterial fitness and β -lactam antibiotic resistance. *Nature communications*, 15(1), 9936. <https://doi.org/10.1038/s41467-024-54219-9>
- Tacconelli, E., Carrara, E., Savoldi, A., Kattula, D., and Burkert, F. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. *The Lancet Infectious Diseases*, 22(6), e198-e207. [https://doi.org/10.1016/S1473-3099\(22\)00173-2](https://doi.org/10.1016/S1473-3099(22)00173-2)
- Tacconelli, E., *et al* (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet. Infectious diseases*, 18(3), 318–327. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3)
- Tang, Y., *et al* (2017). *Detection methods for Pseudomonas aeruginosa: history and future perspective*. *RSC Advances*, 7(82), 51789–51800. <https://doi.org/10.1039/C7RA09064A>
- Thrane, S. W., *et al* (2016). Application of Whole-Genome Sequencing Data for O-Specific Antigen Analysis and In Silico Serotyping of *Pseudomonas aeruginosa* Isolates. *Journal of clinical microbiology*, 54(7), 1782–1788. <https://doi.org/10.1128/JCM.00349-16>

- Tian, Z. X., Yi, X. X., Cho, A., O'Gara, F., and Wang, Y. P. (2016). CpxR Activates MexAB-OprM Efflux Pump Expression and Enhances Antibiotic Resistance in Both Laboratory and Clinical nalB-Type Isolates of *Pseudomonas aeruginosa*. *PLoS pathogens*, 12(10), e1005932. <https://doi.org/10.1371/journal.ppat.1005932>
- Turton, J. F., *et al* (2015). High-Resolution Analysis by Whole-Genome Sequencing of an International Lineage (Sequence Type 111) of *Pseudomonas aeruginosa* Associated with Metallo-Carbapenemases in the United Kingdom. *Journal of clinical microbiology*, 53(8), 2622–2631. <https://doi.org/10.1128/JCM.00505-15>
- Wilson, M. T., and Hamilos, D. L. (2014). The nasal and sinus microbiome in health and disease. *Current allergy and asthma reports*, 14(12), 485. <https://doi.org/10.1007/s11882-014-0485-x>
- World Health Organization. (2016). *High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting*. Geneva: WHO Press. <https://apps.who.int/iris/handle/10665/250644>
- World Health Organization. (2019). *No time to wait: Securing the future from drug-resistant infections*. WHO. <https://www.who.int/publications/i/item/no-time-to-wait-securing-the-future-from-drug-resistant-infections>
- World Health Organization. (2022). Global antimicrobial resistance and use surveillance system (GLASS) report 2022. World Health Organization.
- World Health Organization. (2023). Antimicrobial resistance. <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
- Wyllie, A. L *et al* (2020). Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *The New England journal of medicine*, 383(13), 1283–1286. <https://doi.org/10.1056/NEJMc2016359>
- Xu, J., Moore, J. E., Murphy, P. G., Millar, B. C., and Elborn, J. S. (2004). Early detection of *Pseudomonas aeruginosa*—comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis. *Annals of Clinical Microbiology and Antimicrobials*, 15(1), 1-5.
- Yoo, B. B, *et al* (2024). Performance evaluation of the Streck ARM-D[®] Kit, β -Lactamase for molecular detection of acquired β -lactamase genes. *Journal of global antimicrobial resistance*, 39, 54–58. Advance online publication. <https://doi.org/10.1016/j.jgar.2024.08.004>
- Yu, L., *et al* (2024). Prevalence, antimicrobial resistance, and genomic characterization of *Salmonella* strains isolated in Hangzhou, China: a two-year study. *Annals of clinical microbiology and antimicrobials*, 23(1), 86. <https://doi.org/10.1186/s12941-024-00748-6>

Zellweger, R. M, *et al* (2017). A current perspective on antimicrobial resistance in Southeast Asia. *The Journal of antimicrobial chemotherapy*, 72(11), 2963–2972. <https://doi.org/10.1093/jac/dkx260>

